Congruence Therapeutics has raised $39.5 million in a funding round to advance its portfolio of small molecule correctors into clinical trials[2]. The funding is intended to support the advancement of these drugs to the clinical phase[1][2]. The company uses the proprietary Revenir™ computational tool for drug discovery targeting genetically validated targets[1]. The portfolio includes candidate CGX-926, a first-in-class oral MC4R corrector for the treatment of genetic obesity, which is proceeding to a Phase 1b clinical trial[1][2]. Other indications include GBA Parkinson's disease, α1-antitrypsin deficiency and oncological diseases[1]. Congruence also leads cooperation on the development of correctors for cancer diseases with Ono Pharmaceuticals and for metabolic targets with an unknown pharmaceutical company[1][2]. Investors include Amplitude Ventures, Lumira Ventures and others[1].